Fortress Biotech, Inc.
FBIO
$1.81
-$0.02-1.09%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -6.95% | -3.48% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -13.10% | 3.36% | |||
| Cost of Revenue | -28.32% | -17.34% | |||
| Gross Profit | 49.88% | 2,985.29% | |||
| SG&A Expenses | 10.75% | 5.36% | |||
| Depreciation & Amortization | -68.90% | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.61% | -6.82% | |||
| Operating Income | -16.84% | 13.56% | |||
| Income Before Tax | 4.96% | 2.43% | |||
| Income Tax Expenses | -- | 386.96% | |||
| Earnings from Continuing Operations | 6.17% | 1.42% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -27.84% | 41.39% | |||
| Net Income | -56.45% | 47.42% | |||
| EBIT | -16.84% | 13.56% | |||
| EBITDA | -17.53% | 14.96% | |||
| EPS Basic | -29.53% | 51.40% | |||
| Normalized Basic EPS | -127.71% | 382.06% | |||
| EPS Diluted | -29.53% | 51.40% | |||
| Normalized Diluted EPS | -127.71% | 382.06% | |||
| Average Basic Shares Outstanding | 1.68% | 32.06% | |||
| Average Diluted Shares Outstanding | 1.68% | 32.06% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||